The Oncology Marketing Strategies U.S. 2008 report provides leading-edge research and analysis on critical reimbursement, pricing, and competitive issues affecting the cancer drug market in the United States. This ongoing, timely information helps marketing and sales professionals better position themselves for success in the increasingly scrutinized and regulated oncology marketplace.
Key Benefits:
Understand the implications for manufacturers of new government policies as well as public and private sector reimbursement trends, including Medicare reform (e.g., Part D, ESA rulings)
Assess the pros and cons of product marketing channel strategies, including specialty pharmacies, distributors, and wholesalers
Evaluate the relative importance of key physician and patient influencers, including patient assistance plan and reimbursement support providers, GPOs, and advocacy groups
Identify key sales and marketing targets (community and institutional customers) that ultimately utilize oncology drug products
Appreciate emerging strategic opportunities to build a cancer franchise and drive product utilization
Access comprehensive market intelligence to increase sales and marketing ROI, including comprehensive profiles of leading oncology market players such as pharmaceutical manufacturers; specialty, mail order and retail pharmacies; PBMs; government and commercial payers; wholesalers; patient assistance program/reimbursement services vendors; and other stakeholders
Unique Features
Direct access to the industry’s leading cancer marketing analytics team
Ongoing series of topical briefings covering the most pressing issues to oncology manufacturers
Regular in-person updates on reimbursement trends and policy developments, and other research highlights with custom recommendations tailored to address client needs
Inside views of key customer groups and national
accounts
For more information on MattsonJack DaVinci's Oncology Marketing Strategies or other multiclient offerings, phone 650.403.7001 or e-mail info@mattsonjack.com.